Flovent Diskus 250 is a drug owned by Glaxo Group Ltd England Dba Glaxosmithkline. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 23, 2016. Details of Flovent Diskus 250's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5873360 (Pediatric) | Inhalation device |
Aug, 2016
(8 years ago) |
Expired
|
| US5873360 | Inhalation device |
Feb, 2016
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Flovent Diskus 250 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Flovent Diskus 250's family patents as well as insights into ongoing legal events on those patents.
Flovent Diskus 250's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Flovent Diskus 250's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 23, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Flovent Diskus 250 Generic API suppliers:
Fluticasone Propionate is the generic name for the brand Flovent Diskus 250. 13 different companies have already filed for the generic of Flovent Diskus 250, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Flovent Diskus 250's generic
Alternative Brands for Flovent Diskus 250
There are several other brand drugs using the same active ingredient (Fluticasone Propionate) as Flovent Diskus 250. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||||
|---|---|---|---|---|---|---|---|---|
| Fougera Pharms |
| |||||||
| Glaxo Grp Ltd |
| |||||||
| Mylan Speciality Lp |
| |||||||
| Optinose Us Inc |
| |||||||
| Teva Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fluticasone Propionate, Flovent Diskus 250's active ingredient. Check the complete list of approved generic manufacturers for Flovent Diskus 250
About Flovent Diskus 250
Flovent Diskus 250 is a drug owned by Glaxo Group Ltd England Dba Glaxosmithkline. Flovent Diskus 250 uses Fluticasone Propionate as an active ingredient. Flovent Diskus 250 was launched by Glaxo Grp Ltd in 2000.
Approval Date:
Flovent Diskus 250 was approved by FDA for market use on 29 September, 2000.
Active Ingredient:
Flovent Diskus 250 uses Fluticasone Propionate as the active ingredient. Check out other Drugs and Companies using Fluticasone Propionate ingredient
Dosage:
Flovent Diskus 250 is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.25MG/INH | POWDER | Prescription | INHALATION |